UNIMECH AEROSPACE AND MANUFACTURING LTD.
Ventura
IPO NOTE
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
20 Dec 2024 | Unimech Aerospace |
Ventura
|
1048.80 |
IPO Subscribe
|
|||||||
20 Dec 2024 | Unimech Aerospace |
KRChoksey
|
1048.80 |
IPO Subscribe
|
IPO Note
KRChoksey
Unimech Aerospace and Manufacturing Limited is an engineering solutions company that specializes in the manufacturing and supply of critical parts for the aerospace, defense, energy, and semiconductor industries.
The company has "build to print" capabilities, where they manufacture products based on client designs, and "build to specifications" capabilities, where they assist clients in designing the products to be manufactured. |
||||||
20 Dec 2024 | Unimech Aerospace |
SBI Securities
|
1048.80 |
IPO Subscribe
|
|||||||
19 Dec 2024 | Ventive Hospitality Ltd. |
HDFC Securities
|
774.20 |
IPO Note
|
IPO Note Ventive Hospitality Limited 20122024
HDFC Securities
Issue Snapshot: Issue Open: December 20 December 24, 2024 Price Band: Rs. 610 643 (Discount of Rs 30 per share for all eligible employees) *Issue Size: Up to Rs. 1600.0 cr (Entirely fresh issue including employee reservation of upto Rs 1.0 cr) Reservation for: QIB alteast 75% eq sh Non-Institutional upto 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail upto 10% eq sh Face Value: Rs 1 Book value: Rs 289.56 (September 30, 2024) Bid size: - 23 equity shares and in multiples thereof 100% Book built Issue IPO Note Ventive Hospitality Limited
|
||||||
19 Dec 2024 | Transrail Lighting Ltd. |
HDFC Securities
|
474.30 |
IPO Note
|
IPO Note Transrail Lighting Limited 20122024
HDFC Securities
Issue Snapshot: Issue Open: December 19 December 23, 2024 Price Band: Rs. 410 432 *Issue Size: Up to Rs 838.91 cr (Fresh issue of Rs 400 cr + Offer for sale of 1.02 cr shares including employee reservation of upto Rs. 19 crore) Reservation for: QIB upto 50% eq sh Non-Institutional upto 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail atleast 35% eq sh Face Value: Rs 2 Book value: Rs 92.02 (June 30, 2024) Bid size: - 34 equity shares and in multiples thereof 100% Book built Issue Capital Structure: Pre Issue Equity: Rs.25.00 cr *Post issue Equity: Rs. 26.85 cr Listing: BSE & NSE Book Running Lead Managers: Inga Ventures Private Ltd, Axis Capital Ltd, HDFC Bank Ltd, IDBI Capital Markets & Securities Limited Sponsor Bank: Axis Bank Ltd & ICICI Bank Ltd Registrar to issue: Link Intime India Private Limited IPO Note Transrail Lighting Limited
|
||||||
19 Dec 2024 | Senores Pharmaceuticals Ltd. |
SBI Securities
|
549.50 |
IPO Subscribe
|
|||||||
19 Dec 2024 | Ventive Hospitality Ltd. |
KRChoksey
|
774.20 |
IPO Note
|
IPO Note
KRChoksey
Ventive Hospitality Limited ( VHL) is a leading hospitality asset owner with a primary focus on luxury properties across both business and leisure segments, operating assets under global brands like Marriott, Hilton, Minor, and Atmosphere.
Its portfolio comprises 11 operational properties in India and the Maldives, totalling 2,036 keys, with a strong emphasis on luxury assets, such as JW Marriott Pune, The Ritz-Carlton Pune, and Conrad Maldives. |
||||||
19 Dec 2024 | Carraro India Ltd. |
KRChoksey
|
306.00 |
IPO Note
|
IPO Note
KRChoksey
Carraro India Limited, incorporated in 1997 as a private limited entity, has grown into a leading player in the manufacturing of transmission systems and components for agricultural and construction machinery.
The company operates as part of the globally renowned Carraro Group, leveraging its parent company's technical expertise and international presence to deliver high-quality products tailored to customer needs. |
||||||
19 Dec 2024 | Senores Pharmaceuticals Ltd. |
KRChoksey
|
549.50 |
IPO Note
|
IPO Note
KRChoksey
Senores Pharmaceuticals focuses on generic drugs and specialty medications across various therapeutic areas, including cardiovascular, diabetes, gastroenterology, and critical care injectables. The company manufactures products at its FDA-approved facilities, with a significant presence in regulated markets like the US, UK, and Canada.
|
||||||
18 Dec 2024 | DAM Capital Advisors Ltd. |
AUM Capital
|
220.50 |
IPO Subscribe
|
|||||||
more
loading
|